JCI Insight · 2023 · 15 citations · 39 references
Life SciencesImmunologyPathologyAutoimmunityImmunopharmacologyImmunotherapyAutoimmune Disease ImmunotherapyB Cell ActivationB Cell BiologyB Cell DevelopmentHumoral ImmunityTherapeutic Monoclonal AntibodiesAnti-cd20 Antibody TherapyAnti-cd20 TherapyB Cell - Mediated AutoimmunityB Cell DysfunctionB-cell Depleting AgentsB-cell Targeted TherapyCell ActivationImmune Cell Depletion
B cells contribute to multiple aspects of autoimmune disorders, and B cell-targeting therapies, including B cell depletion, have been proven to be efficacious in treatment of multiple autoimmune diseases. However, the development of novel therapies targeting B cells with higher efficacy and a nondepleting mechanism of action is highly desirable. Here we describe a nondepleting, high-affinity anti-human CD19 antibody LY3541860 that exhibits potent B cell inhibitory activities. LY3541860 inhibits B cell activation, proliferation, and differentiation of primary human B cells with high potency. LY3541860 also inhibits human B cell activities in vivo in humanized mice. Similarly, our potent anti-mCD19 antibody also demonstrates improved efficacy over CD20 B cell depletion therapy in multiple B cell-dependent autoimmune disease models. Our data indicate that anti-CD19 antibody is a highly potent B cell inhibitor that may have potential to demonstrate improved efficacy over currently available B cell-targeting therapies in treatment of autoimmune conditions without causing B cell depletion.
39
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
ME Reff, K Carner, KS Chambers et al. · Blood · 1994 · 1.9K citations · Full text
Life Sciences, Immunology, Pathology +14
An Antibody-Deficiency Syndrome Due to Mutations in the<i>CD19</i>Gene
Menno C. van Zelm, İsmail Reisli, Mirjam van der Burg et al. · New England Journal of Medicine · 2006 · 545 citations · Full text
Life Sciences, Genetics, Immunology +17